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Summary Sensitivity to platinum-containing drugs is believed to be a function of how much drug enters
the cell, the extent of DNA adduct formation and the rate at which DNA is repaired. Activation of protein
kinase C by 12-0-tetradecanoyl-phorbol-13-acetate (TPA) was found to enhance the sensitivity of human
ovarian carcinoma 2008 cells to cisplatin (DDP), carboplatin (CBDCA) and (glycolato-O,O') diamminep-
latinum(II) (254-S). TPA was able to enhance the sensitivity of the DDP-resistant 2008/C13*5.25 subline to
each of the three drugs to the same extent as for the 2008 cells. TPA produced no significant change in the
uptake of [3H]cis-dichloro(ethylenediamine)-platinum(II) ([3H]DEP) or CBDCA. It did not alter glutathione
content or glutathione-S-transferase activity, and induced rather than suppressed metallothionein IA mRNA
levels. TPA did increase the formation of intrastrand guanine-guanine cross-links by a factor of 1.5 ± 0.3
(s.d.), and reduced the fraction of intrastrand adducts removed from DNA over the subsequent 24 h by a
factor of 1.3 ± 0.2 (s.d.) (n = 4; P<0.05), however, these effects were too small to account for the degree of
TPA-induced sensitisation. These results indicate that the mechanism of TPA-induced sensitisation is not
specific to any one structural form of platinum-containing drug, and that it is not readily explicable on the
basis of an effect on the four major parameters currently believed to regulate DDP sensitivity.
DDP has activity against a relatively broad range of tumours
(Loehrer & Einhorn, 1984), and the antineoplastic activity of
this drug is generally considered to result from its reaction
with DNA. The majority of the adducts formed in DNA are
guanine-guanine intrastrand cross-links; less than 1% of the
adducts are interstrand cross-links, and a small fraction are
DNA-protein cross-links (Andrews & Howell, 1990). How
these cross-links cause cell death is unknown.
Four biochemical mechanisms have been identified that
can influence the sensitivity of cells to DDP (reviewed in
Andrews & Howell, 1990): (1) impairment of cellular uptake;
(2) elevation of glutathione-S-transferase (GSH) activity
(Godwin et al., 1992); (3) elevation of metallothioneins; and
(4) variations in DNA repair. In bacteria, defects in the
repair of damaged DNA are associated with hypersensitivity
to DDP (Beck & Brubaker, 1973). Likewise, defects in DNA
repair processes in mammalian cells render them hypersen-
sitive to DNA-damaging agents (Meyn et al., 1982). Thus,
DNA repair processes are important determinants of the
cytotoxic effects of DNA-damaging agents in&general, and of
cisplatin in particular (Plooy et al., 1985; S&renson & East-
man, 1988). Furthermore, an increase in DNA repair cap-
ability has been reported as a mechanism of resistance to
genotoxic agents in DDP-resistant murine leukaemia L1210
cells (Sheibani et al., 1989) and in DDP-resistant human
ovarian cancer cells A2780cP cells (Masuda et al., 1990).
We have previously reported that activation of protein
kinase C (PKC) by TPA enhances the DPP sensitivity of the
human ovarian carcinoma cell line 2008 (Ishonishi et al.,
1990), indicating that the PKC signal transduction pathway
can regulate one or more of the biochemical events that
determine the ability of DDP to cause cell death. This obser-
vation has been confirmed in another laboratory (Basu et al.,
1990). In this paper we report that activation of PKC can
also sensitise cells to CBDCA and 254-S, two analogues
whose biochemical pharmacology differs from that of DDP.
We also report that the sensitising effect of TPA cannot be
accounted for by effects on any of the four major parameters
currently thought to regulate DDP sensitivity.
Materials and methods
Materials
TPA was purchased from Sigma (St Louis, MO, USA). DDP
and CBDCA were generous gifts from Bristol-Myers Squibb,
Japan. 254-S was a generous gift from Shionogi, Japan.
Monochlorobimane (MCB) was purchased from Molecular
Probes (Eugene, OR, USA). A stock solution of MCB was
prepared in ethanol (20mM) and was kept at 0-5°C, pro-
tected from light. ['4C]thymidine was obtained from New
England Nuclear (Boston, MA, USA). [3H]DEP (specific
activity > 16.4 Ci mmol-', an analogue of cis-diamminedi-
chloroplatinum(II) (DDP) that produces adducts at identical
sites in DNA, was synthesised as previously reported (East-
man, 1983).
Tumour cell lines
The human cell line 2008 was established from a patient with
a serous cystadenocarcinoma of the ovary (Disaia et al.,
1972). The characteristics of this line and its growth condi-
tions have been previously described (Andrews et al., 1985).
Sensitivity to the cytotoxic effect of the platinum compounds
was determined by clonogenic assay as previously described
(Isonishi et al., 1990). All experiments were done using tri-
plicate cultures of cells in logarithmic growth, and each
experiment was repeated a minimum of three times.
[3H]DEP and CBDCA uptake
Subconfluent monolayers of 2008 cells were treated with 37°C
RPMI-1640 medium containing 5 tLM [3H]DEP (10 yCi ml-')
for 1 h. The medium was then aspirated, and the cells were
washed rapidly four times with 4°C phosphate-buffered saline
(PBS). The cells were scraped off the dishes in 200tlI of PBS
and sonicated to lyse the cells; one aliquot of 25 IlI was used
to quantitate drug (liquid scintillation counting for total
[3H]DEP and another 25fil aliquot was used for determina-
tion of protein content by the method of Bradford (1976).
Glutathione content andglutathione-S-transferase activity
GSH content was measured by adjusting cells to 106ml-'
and staining them with 25 tM MCB in complete medium at
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room temperature for the indicated time; relative cellular
fluorescence was then immediately measured on a flow cyto-
meter (Cytofluoro Graf Ils, Orthodiagnostic System) with
excitation and emission settings of 385 and 480 nm respec-
tively (Rice et al., 1986; Shrieve et al., 1988). Values were
converted from log fluorescence to linear fluorescence inten-
sity by application of the equation x= iO[(-20)160], where x is
the relative linear fluorescent intensity and y is the mean log
channel number. Cells that were non-viable on the basis of
forward and right-angle light scatter were excluded from
analysis.
The forward rate constant for the conjugation of MCB by
glutathione S-transferase is given by the equation K = (initial
rate)/[MCB][GSH]. Since the GSH content in the uninduced
and induced state turned out to be the same, and the MCB
concentration was identical, the effect of TPA treatment on K
could be estimated from its effect on the initial slope of the
conjugation curve.
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Measurement ofmetallothionein messenger RNA
Northern blots containing 10 ,sg of total cellular RNA were
prepared by standard techniques and hybridised sequentially
to probes for human metallothionein IIA and P-actin (Kaline
& Richards, 1982); Gunning et al., 1983), the latter of which
was used to control for lane loading.
Carboplatin (CBDCA)
NH3
0
Pt
Extent ofintrastrand cross-linkformation and repair
Subconfluent monolayers of 2008 cells were cultured with
complete RPMI containing 1 nCi of ['4C]thymidine in 75 cm2
culture flasks for 72 h. The medium was then changed and
the cells were incubated at 37°C for h with 10ILCi ml-'
[3H]DEP in the presence or absence of 0.1 ILM TPA. Cells
were harvested either immediately or 24 h after the treatment
by trypsinisation, and washed twice with ice-cold PBS. Int-
rastrand guanine-guanine adducts were quantitated as
previously described (Eastmen, 1983, 1991). Briefly, DNA
was isolated, digested to nucleotides with deoxyribonuclease I
(bovine pancreas) and P1 nuclease, and then converted to
nucleosides with alkaline phosphatase. The [3H]DEP-labelled
guanine-guanine dinucleotide was separated and quantitated
by high-performance liquid chromatography (HPLC). The
extent of intrastrand cross-link removal was corrected for
new DNA synthesis occurring during the repair period by
expressing the amount of [3H]DEP as a function of the
amount of [14C]thymidine present at each time point.
Results
NH3 / 0
254-S
Figure 1 The structures of DDP, CBDCA and 254-S
Figure 3 shows a comparison of the ability of TPA to
sensitise DDP-resistant 2008/C13*5.25 cells to DDP CBDCA
and 254-S. At the time of this testing, 2008/C13*5.25 cells
were 4.2 ± 0.8 (s.d.)-fold resistant to DDP, 2.1 + 0.2 (s.d.)-
fold cross-resistant to CBDCA and 6.3 ± 1.5 (s.d.)-fold cross-
resistant to 254-S. TPA sensitised the 2008/C13*5.25 cells by
a factor of 2.7 ± 0.5 (s.d.) for DDP, 3.2 ± 0.4 (s.d.) for
CBDCA and 2.5 ± 0.6 (s.d.) for 254-S (Table I). All these
differences were statistically significant (P<0.05). Thus, TPA
was as effective at sensitising the resistant cells as it was at
sensitising the sensitive 2008 parental cells, and therefore the
mechanism must be independent of those factors that render
the 2008/Cl3*5.25 cells resistant.
Modulation ofsensitivity by TPA
Figure 1 shows the structures of DDP, CDBCA and 254-S.
All three are platinum(II) compounds, but each has a
different leaving group. In the low-chloride environment of
the cytosol, aquation displaces the two chlorides from DDP,
the cyclobutane dicarboxylate from CBDCA and the glycol-
ato group from 254-S. Thus all three drugs generate the same
Pt(NH3)2(H20)2+ + reactive species, and produce the same
types of adducts in DNA. Figure 2 shows a comparison of
the effect of a 1 h concurrent exposure to 0.1 LM TPA on the
sensitivity of human ovarian carcinoma 2008 cells to DDP,
CBDCA and 254-S. TPA sensitised the cells to DDP by a
factor of 2.5 0.7 (s.d.), and to CBDCA and 254-S by
factors of 2.8 0.6 (s.d.) and 2.3 ± 0.6 (s.d.) respectively. The
actual IC,o values are presented in Table I. Sensitisation was
dependent on the concentration of TPA; the effect reached a
plateau at 0.1 tLM, and further increases in TPA concentra-
tion did not cause any further enhancement of sensitivity
(data not shown). The fact that TPA was able to sensitise
cells to all three agents, and by approximately equivalent
degrees, indicates that the effect was not specific to any one
type of leaving group.
Effect of TPA on cellular uptake of[3H]DEP
The human ovarian carcinoma 2008 cells were incubated
with 5 tLM [3H]DEP in the presence or absence of 0.1 M TPA
(or an appropriate dilution of acetone alone as a vehicle
control). At 60 min the TPA-treated cells contained
113 ± 17% (s.d.) of that in the controls. Thus, there was no
discernible effect of TPA on [3H]DEP at uptake. We have
previously shown that such an exposure to TPA by itself
does not alter either the cloning efficiency or growth rate of
the 2008 cells (Isonishi et al., 1990).
Effect of TPA on cellular GSH content andglutathione-S-
transferase activity
MCB reacts quantitatively with GSH via glutathione S-trans-
ferase to form a fluorescent product readily quantitated by
flow cytometry (Rice et al., 1986; Shrieve et al., 1988). The
human ovarian 2008 cells were stained with MCB for various
periods of time and relative fluorescence was determined
immediately by flow cytometry. Figure 4 shows a represen-
tative experiment indicating that maximum staining was
obtained by 50 min, and this staining time was used for all
\CIPKC MODULATION OF PLATINUM(II) DRUG SENSITIVITY 219
100'
10-
1*
CBDCA
10 20 30 40 50 60
254-S
0 2 4 6 . 12
0 2 4 6 8 10 12
Platinum concentration (>M)
Figure 2 Dose-response curves for human ovarian carcinoma 2008 cells exposed for 1 h to either DDP, CBDCA or 254-S alone
(0) or concurrently to the platinum-containing drug and 0.1 AM TPA (@). Each point represents the mean of three experiments
each performed with triplicate cultures. Vertical bars, s.d. Data for DDP from Isonishi et al. (1990) are shown for comparison.
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Figure 3 Dose-response curves for human ovarian carcinoma 2008/Cl3*5.25 cells exposed for I h to either DDP, CBDCA or
254-S alone (0) or concurrently to the platinum-containing drugs and 0.1 tLM TPA (0). Each point represents the mean of three
experiments each performed with triplicate cultures. Vertical bars, s.d.
Table I IC50 values for DDP, CBDCA and 254-S
IC50 (jAM) (mean ± s.d.)
Cell TPA
type exposurea DDP CBDCA 254-S
2008 -
+ 3.1±0.6 22.3 0.1 8.5 2.7
2008/C13*5.25 - 1.2 ± 0.4 7.9 ± 2.4 3.7 ± 0.6
+ 13.1
± 2.7 46.2
± 5.2 53.3
± 12.6
4.9 1.4 14.6 3.2 21.5 3.2
aTPA, 0.1 LM
subsequent experiments. The GSH content of cells treated
with 0.1 M TPA for 1 h was 98.1 ± 24.7% (s.d.; n = 3) of
that in the untreated cells. Thus, TPA treatment did not alter
GSH content significantly.
Since there was no difference in GSH content, the initial
rate of reaction between GSH and MCB can be used to
estimate the rate constant for the glutathione S-transferase-
mediated reaction of MCB with GSH, assuming that the
MCB has equal access to the GSH in the presence and
absence of TPA. The ratio of glutathione S-transferase
activity in 2008 cells treated with or without TPA for 1 h was
1.02 ± 0.21 (s.d.; n = 3). Thus, TPA treatment did not pro-
duce a significant change in glutathione S-transferase when
activity was assayed in this manner.
Effect of TPA on cellular metallothionein mRNA
RNA was harvested from 2008 cells 24 h after a 1 h exposure
to 0.1 AM TPA, and Northern blots were probed for the level
of metallothionein IIA message, and subsequently with a
probe for P-actin to confirm equivalent lane loading. Figure 5
shows that TPA increased the level of metallothionein IIA in
these cells, which is the opposite of what might be expected if
TPA-induced sensitisation was working through reduction of
metallothionein IIA protein content.
Effect of TPA on [3H]DEP intrastrand adductformation and
repair
Intrastrand DNA cross-link formation can be quantitated
using [3H]DEP as reported by Eastman (1983, 1991). This
technique permits specific quantitation of the most abundant
adduct, the guanine-guanine intrastrand cross-link. The
2008 cells were incubated with or without 0.1 laM TPA for
1 h concurrent with a 1 h incubation with 5 ILM [3H]DEP, and
the extent of intrastrand cross-link formation was deter-
mined. At the end of a 1 h incubation with [3H]DEP, un-
treated 2008 cells contained 48.6 ± 0.4 (s.d.; n = 4) d.p.m. per
nmol of DNA phosphate, whereas 2008 cells exposed to
0.1 AM TPA for 1 h concurrently with the [3H]DEP contained
67.9 ± 6.8 (s.d.; n =4) d.p.m. per nmol phosphate. Thus,
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Figure 4 Time course of the glutathione S-transferase-mediated
conjugation of MCB in 2008 cells in the presence (0) or absence
(0) of 1 h preincubation with 0.1 iLM TPA.
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Figure 5 Northern blot showing induction of metallothionein
(MT) lA messenger RNA by TPA. Lanes 3, 2008 cells treated
with vehicle only; 4-6, cells treated with TPA 0.1I im for 24 h.
despite the fact that TPA increased total cellular [3H]DEP
uptake by only 13%, it increased guanine-guanine intra-
strand adduct formation by 1.5 ±0.3 (s.d.)-fold (n =4;
P<0.05). However, this change was significantly smaller
than the degree of enhanced sensitivity to DDP.
The percentage of guanine-guanine intrastrand adducts
remaining was determined under conditions in which 2008
cells were first exposed to [IH]DEP for h, with or without
concurrent TPA, and then incubated for 24 h in drug-free
medium. The extent of cross-link removal was normalised for
differences in DNA synthesis during the repair period by
prelabelling the DNA with ['4C]thymidine and determining
the ratio of [3HJDEP to ['4C]thymidine at the beginning and
end of the repair period. In the absence of TPA treatment,
55.5 ± 7.6% (s.d.; n = 4) of the guanine-guanine intrastrand
cross-links present at the end of the h [3H]DEP incubation
were still present 24 h later, whereas when TPA was present
during the [3H]DEP exposure 71.0 ± 10.0% (s.d.; n = 4) of
the intrastrand cross-links remained (P
= 0.05). Thus, a h
TPA exposure reduced the removal of intrastrand cross-links
over the ensuing 24 h only by a factor of 1.3 ± 0.2 (s.d.),
which was not enough to account for the 2.5-fold enhance-
ment of sensitivity to DDP.
Discussion
Concurrent exposure of cells to TPA and DDP for h
enhances the DDP sensitivity of human ovarian carcinoma
2008 cells by a factor of 2.5-fold when sensitivity is quan-
titated using a clonogenic assay (Isonishi et al., 1990). This
drug interaction is truly synergistic when formally examined
by isobologram or median effect analysis (Berebaum, 1989;
Isonishi et al., 1990). The studies reported here indicate that
the sensitising effect of TPA is not limited to DDP, but
occurs also with two other platinum(II)-containing analo-
gues, both of whose biochemical pharmacology differs from
that of DDP.
The fact that the magnitude of the TPA-induced sensitisa-
tion was approximately equal for DDP, CBDCA and 254-S
indicates that the mechanism of this effect in not influenced
by the substantial differences in the rates ofhydration for the
three drugs. Likewise, the fact that TPA was able to enhance
the sensitivity of the 2008/Cl3*5.25 cells by approximately
the same magnitude as for the 2008 cells indicates that the
mechanism of the TPA effect is independent of the bio-
chemical changes that account for the DDP-resistant
phenotype. The 2008/C13*5.25 cells are known to have
impaired DDP uptake (Mann et al., 1990) and a small inc-
rease in GSH (Andrews et al., 1988), but the major
mechanism causing resistance in these cells is unknown.
The results reported here establish that the sensitising
effect of TPA does not involve a change in GSH content or
glutathione S-transferase activity. Although metallothionein
IIA mRNA and not protein levels were measured in this
study, given that TPA causes a substantial increase in mes-
sage level it seems unlikely that it would have decreased the
metallothionein IIA protein level. In other mammalian cell
systems an increase in metallothionein IA message has been
closely linked to an increased rather than a decreased level
(Garrett et al., 1992). Sensitisation was not associated with a
significant change in [3H]DEP uptake, but TPA did cause a
1.5-fold increase in intrastrand adduct formation, and a 1.3-
fold decrease in the extent of adduct removal at 24 h. The
magnitude of these effects are individually all relatively small,
and the assays for these changes subject to substantial
variance. Thus the biological significance of these changes
cannot be determined, but it is noteworthy that in neither
case did the magnitude of the change match the degree of
enhanced sensitivity.
How TPA incerases intrastrand guanine-guanine adduct
formation to a greater extent than it increases total [3H]DEP
accumulation is currently unknown. DDP and [3H]DEP enter
cells relatively slowly. One possibility is that TPA alters the
extent of intracellular inactivation of DDP through forma-
tion of complexes with thiol-containing proteins. Alterna-
tively, TPA may make it easier for [3H]DEP to react with
DNA by changing chromatin conformation. TPA, acting
indirectly through TPA-responsive elements in promoters,
increases the transcriptional activity of many genes (Lee et
al., 1987); such activation may expose such genes to attack
by aquated [3H]DEP. However, unless the activated genes are
extraordinarily susceptible to platination, since they probably
constitute a small fraction of the total DNA target, it
appears unlikely that this mechanism by itself could account
for a measurable increase in total genomic intrastrand adduct
formation. PKC has been shown to phosphorylate a variety
of nuclear proteins that may be involved in chromatin con-
formation (Friedberg, 1985), including HI histone (Sahoun et
al., 1983), RNA polymeraseII (Chuang et al., 1987), topoiso-
merase (Sahyoun et al., 1986; Samuels et al., 1989), and
DNA polymerase (Krauss et al., 1987). Finally, it is impor-
tant to note that, in addition to PKC, n- and P-chimaerin
have now been identified as targets for the binding of TPA
(Ahmed et al., 1993; Leung et al., 1993), and it is possible
that the effects on platinum-containing drug sensitivity are
mediated by activation of signal transduction pathways other
than those in which PKC is involved.
While the results reported here establish that TPA
enhances the sensitivity of human ovarian cells to three
different platinum(II)-containing drugs in both sensitive and
resistant cells, the mechanism of this effect remains to be
defined, and it-is important to emphasise that PKC may be
producing other changes in cellular metabolism, unrelated to
the biochemical pharmacology of these drugs, that also
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